Document is current

Any future updates will be listed below

Correction: Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy

Crossref DOI link: https://doi.org/10.1007/s41669-025-00596-w

Published Online: 2025-08-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark